

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 245553US0CONT		SERIAL NO. 10/743,997	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Yukio NIHEI, et al.			
				FILING DATE December 24, 2003		GROUP 1618	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
/S.G./	AA	5,525,632	06/11/1996	OBSUMI, et al.			
/S.G./	AB	5,731,353	03/24/1998	OHSUMI, et al.			
/S.G./	AC	5,674,906	10/07/1997	HATANAKA, et al.			
/S.G./	AD	6,462,087	10/08/2002	MORINAGA, et al.			
	AF						
	AF						
	AC						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AQ						
	AR						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
/S.G./	AW	HIDEKI, H., et al., "Influence of the Steroid Agent on Cytotoxicity of the Antitumor Agent -Examination in the Human Culture Cell Line," 120 th Annual Meeting of the Pharmaceutical Society of Japan, Summary 4, March 5, 2000, page 83 with English translation					
/S.G./	AX	IWASAKI, S., et al., "Natural Organic Compounds that Affect to Microtubule Functions: Synthesis and Structure-Activity Relationships of Combretastatins, Curacin A and Their Analogs as the Colchicine-site Ligands on Tubulin," Yakugaku Zasshi, Journal of the Pharmaceutical Society of Japan, Vol. 120, No. 10, October 1, 2000, pages 875-889					
/S.G./	AY	KIM, T. J., et al., "Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma," Cancer Res 67:(19), October 1, 2007, pages 9337-9345					
/S.G./	AZ	OHNO, T., et al., "Antitumor and Antivascular Effects of AC-7700, A Combretastatin A-4 Derivative, Against Rat Liver Cancer, Int J Clin, 7, June 2002, pages 171-176					
						<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner _____ Date Considered _____							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 245553US0CONT	SERIAL NO. 10/743,997
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT	Yukio NIHEI, et al.	
		FILING DATE	GROUP	1618
December 24, 2003				
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)				
/S.G./	AAA	HORI, K., et al., "A Novel Combretastatin A-4 Derivative, AC7700, Strongly Stanches Tumour Blood Flow and Inhibits Growth of Tumors Developing in Various Tissues and Organs," British Journal of Cancer, 86, May 20, 2002, pages 1604-1614		
/S.G./	AAB	HORI, K., et al., "Stoppage of Blood flow in 3-methylcholanthrene-induced Autochthonous Primary Tumor Due to a Novel Combretastatin A-4 Derivative, AC7700, and its Antitumor Effect," Med Sci Monit, 7(1), Jan-Feb 2001, pages 26-33		
/S.G./	AAC	NIHEI, Y., et al., "A Novel Combretastatin A-4 Derivatives, AC-7700, Shows Marked Antitumor Activity Against Advanced Solid Tumors and Orthotopically Transplanted," Jpn. J. Cancer Res., September 1999, 90, pages 1016-1025		
/S.G./	AAD	HORI, K., et al., "Tumor Blood Flow Interruption After Radiotherapy Strongly Inhibits Tumor Regrowth," Cancer Sci, Vol. 90, No. 7, July 2000, pages 1485-1491		
/S.G./	AAE	HORI, K., et al., "Differential Relationship Between Changes in Tumour Size and Microcirculatory Functions Induced by Therapy with an Antivascular Drug and with Cytotoxic Drugs: Implications for the Evaluation of Therapeutic Efficacy of AC7700 (AVE8062)," European Journal of Cancer, 39 (13), September 2003, pages 1957-1966		
/S.G./	AAF	MORINAGA, Y., et al., "Combination Effect of AC-7700, A Novel Combretastatin A-4 Derivative, and Cisplatin Against Murine and Human Tumors In Vivo," Cancer Sci, Vol. 94, No. 2, 2003, pages 200-204		
/S.G./	AAG	LAVISSE, S., et al., "Early Quantitative Evaluation of a Tumor Vasculature Disruptive Agent AVE8062 Using Dynamic Contrast-Enhanced Ultrasonography," Investigative Radiology, Vol. 43, No. 2, February 2008, pages 100-111		
/S.G./	AAH	HORI, K., et al., "Microvascular Mechanisms by Which the Combretastatin A-4 Derivative AC7700 (AVE8062) Induces Tumour Blood Flow Stasis," British Journal of Cancer, 89(7), October 6, 2003, pages 1334-1344		
/S.G./	AAI	NIHEI, Y., et al., "Evaluation of Antivascular and Antimitotic Effects of Tubulin Binding Agents in Solid Tumor Therapy," Jpn. J. Cancer Res., 90(12), December 1999, pages 1367-1395		
/S.G./	AAJ	HORI, K., et al., "Antitumor Effects Due to Irreversible Stoppage of Tumor Tissue Blood Flow: Evaluation of a Novel Combretastatin A-4 Derivative, AC7700, Jpn. J. Cancer Res., 90, September 1999, pages 1026-1038		
	AAK			
	AAL			
	AAM			
	AAN			
	AAO			
	AAP			
	AAQ			
Examiner		/Shirley Gembeh/		Date Considered
Date Considered 01/29/2009				
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				